
SK Life Science Unveils Promising Epilepsy Treatment Data at AAN Meeting
SK Life Science, the U.S. subsidiary of South Korea's SK Biopharm, has announced a significant milestone in epilepsy treatment research. On April 7, the company revealed its plans to present pivotal research findings on cenobamate, marketed in the U.S. …